The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07496-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neurological Sciences, 2024. Verfasst von Chananchida Sirilertmekasakul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, 10520, Thailand. Hauptthemen laut MEDLINE: Migraine Disorders, Headache Disorders, Secondary, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: The objective of this systematic review and meta-analysis was to determine whether patients with episodic (EM) or chronic migraine (CM), who were treated with anti-CGRP antibodies, showed a reversal from medication overuse (MO) or medication overuse headache (MOH) status at their baseline to non-overuse status. Furthermore, this study aimed to establish which acute headache medication (AHM) categories responded more effectively to anti-CGRP antibodies. METHODS: A systematic search was conducted in the PubMed database for relevant studies from January 2013 to September 2023. We included phase three randomized controlled trials to examine the role of anti-CGRP antibodies in patients with EM or CM and their MO status. A meta-analysis was conducted to find the association between anti-CGRP antibodies and the number of EM and CM patients with MO or MOH at baseline that reverted to non-MO status or below the MOH threshold. RESULTS: The initial search yielded a total of 345 studies. After removing duplicates and screening with inclusion criteria, 5 studies fulfilled our conditions. Each study reviewed the response to changes in the MO status of patients after receiving anti-CGRP antibodies, including eptinezumab, fremanezumab, galcanezumab, and erenumab, compared to placebo. Our study analyzed three AHM categories: triptans, simple analgesics, and multiple drugs. The overall relative risk (RR) was 1.44 (95% CI, 1.31 to 1.59; p 0.05. Interestingly, this analysis can be interpreted as that anti-CGRP antibodies might not be effective in reducing simple analgesics use in EM or CM patients. Further studies are needed to investigate these matters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, 10520, Thailand.
- Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, 10520, Thailand. wanakorn.ra@kmitl.ac.th.
Zitieren
APA
Sirilertmekasakul, C., Panto, A., Lekhalawan, P., Panyarachun, P., Jindasakchai, P., & Rattanawong, W. (2024). The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial. Neurological Sciences. https://doi.org/10.1007/s10072-024-07496-7
Vancouver
Sirilertmekasakul C, Panto A, Lekhalawan P, Panyarachun P, Jindasakchai P, Rattanawong W. The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial. Neurological Sciences. 2024. doi:10.1007/s10072-024-07496-7
BibTeX
@article{Sirilertmekasakul2024,
author = {Sirilertmekasakul, Chananchida and Panto, Akkanat and Lekhalawan, Pattanan and Panyarachun, Pariyada and Jindasakchai, Porpim and Rattanawong, Wanakorn},
title = {The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07496-7}
}
EUVIMED